Search hospitals > Indiana > Indianapolis
Indiana University
Claim this profileIndianapolis, Indiana 46202
Global Leader in Breast Cancer
Global Leader in Alzheimer's Disease
Conducts research for Fibrosing Colonopathy
Conducts research for Cancer
Conducts research for Newborns
651 reported clinical trials
103 medical researchers
Summary
Indiana University is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Breast Cancer, Alzheimer's Disease, Fibrosing Colonopathy, Cancer, Newborns and other specialties. Indiana University is involved with conducting 651 clinical trials across 1,307 conditions. There are 103 research doctors associated with this hospital, such as Kathy Miller, MD, Nabil Adra, MD, Anita Turk, MD, and Lisa Landrum.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage I
2Alzheimer's Disease
Global Leaderdonanemab
Top PIs
Kathy Miller, MDIndiana University/Melvin and Bren Simon Cancer Center9 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
18 reported clinical trials
57 drugs studied
Nabil Adra, MDIndiana University Melvin and Bren Simon Cancer Center5 years of reported clinical research
Studies Prostate Cancer
Studies Prostatic Neoplasm
14 reported clinical trials
28 drugs studied
Anita Turk, MDIU Health North Hospital6 years of reported clinical research
Studies Parotid Gland Cancer
Studies Colorectal Cancer
14 reported clinical trials
30 drugs studied
Lisa LandrumIndiana University/Melvin and Bren Simon Cancer Center2 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
13 reported clinical trials
28 drugs studied
Clinical Trials running at Indiana University
Breast Cancer
Ovarian Cancer
Chronic Pain
Cancer
Prostate Cancer
Chronic Pancreatitis
Breast cancer
Small Cell Lung Cancer
Pulmonary Embolism
Cystic Fibrosis
Avelumab + Palbociclib/Hydroxychloroquine
for Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Recruiting3 awards Phase 212 criteria
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting1 award Phase 1 & 25 criteria
SRG-514
for Breast Cancer
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Recruiting1 award Phase 13 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Indiana University?
Where is Indiana University located?
Who should I call to ask about financial aid or insurance network?
What insurance does Indiana University accept?
What awards or recognition has Indiana University received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.